Pulmonary Adenocarcinoma With Signet Ring Cell Features
- 1 December 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 38 (12), 1681-1688
- https://doi.org/10.1097/pas.0000000000000280
Abstract
Comprehensive biological characteristics of pulmonary adenocarcinomas with signet ring cell features (SRC+) are not well known. Herein, we systematically evaluated clinical and molecular features of SRC+ cases with particular attention to smoking status. Surgically treated lung adenocarcinomas (n=763) with follow-up ≥5 years in 3 cohorts were reviewed: all patients in 2006 to 2007 (“all-comers,” n=222; 168 ever-smokers), a never-smoker cohort (n=266), and a cohort of ever-smokers (n=275). SRC+ tumors had ≥10% of SRCs agreed by 2 pathologists. SRC+ cases were tested for rearrangement of ALK and ROS1, as well as 187 known mutations in 10 oncogenes including EGFR, KRAS, BRAF, ERBB2, JAK2, AKT1, AKT2, KIT, MET, and PIK3CA. Overall, 53 of 763 cases (7%) were SRC+. In the 2006 to 2007 “all comer” cohort, 9% were SRC+. In the never-smoker cohort, 9% were SRC+. In the smoker cohort, 3% were SRC+. Univariable analysis showed that SRC+ never-smokers had shorter overall and disease-free survival (P=0.006 and 0.0004, respectively), but the significance faded in the multivariable analysis. For the other 2 cohorts, crude 5-year survival was decreased by 6% to 27% in SRC+ cases without reaching statistical significance. In SRC+ tumors, KRAS mutation was most common (29%), followed by ALK (26%), EGFR (18%), ROS1 (6%), BRAF (6%), and PIK3CA (3%). In summary, SRC+ tumors in never-smokers had a worse survival by univariable analysis only. SRC+ cases seemed enriched for ALK+ and ROS1+, and other mutations were generally in keeping with the patient’s smoking status.Keywords
This publication has 31 references indexed in Scilit:
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant KinasesJournal of Clinical Oncology, 2010
- Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the LungJournal of Thoracic Oncology, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- Signet‐ring cell carcinoma component in primary lung adenocarcinoma: potential prognostic factorHistopathology, 2008
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- PIK3CA mutation status in Japanese lung cancer patientsLung Cancer, 2006
- Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung AdenocarcinomaJournal of Thoracic Oncology, 2006
- Primary Lung Carcinoma With Signet-ring Cell Carcinoma ComponentsThe American Journal of Surgical Pathology, 2004